Skip to content

After several years of volatility and unfavorable market dynamics, the initial public offering (IPO) market for medical technology companies is beginning to reopen meaningfully. Following the most recent IPO boom in 2020 and 2021, higher interest rates and inflation brought new IPO issuances to a near standstill from 2022 to 2024. During that period, many medtech companies postponed plans to go public, creating a significant backlog of IPO deals.

LINKS

Read “From Innovation to IPO: A Strategic Checklist for Medtech Companies,” co-authored by David J. Dykeman and Michael Minahan, and published by Medical Product Outsourcing.

Tags: GT Boston, GT Insight, Published Article
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of David J. Dykeman David J. Dykeman

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice

…

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology.

David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multi-national corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.

An author of over 50 articles and a speaker at over 45 conferences on intellectual property law, David is the founding co-chair of the ABA’s Medical Devices Committee. He was honored as one of Boston’s “40 Under 40” innovative business leaders by the Boston Business Journal and was named to the “40 Medtech Innovators Under 40” list by Medical Device & Diagnostic Industry (MD+DI) Magazine. David has also been named one of the top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine, an “IP Star” by Managing IP magazine, a “Life Science Star” by LMG Life Sciences, and one of the World’s Leading IP Strategists in the IAM 300.

Read more about David J. Dykeman
Show more Show less
Related Posts
biotechnology
Building Strong Medtech Partnerships: Keys to Successful Contract Manufacturing Agreements
May 26, 2026
DNA
Building a Future-Proof IP Strategy for AI in Medtech
May 12, 2026
DNA
Why Patent Portfolios are Crucial for Life Science Innovators
April 26, 2026